These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38072190)

  • 1. Ser235 phosphorylation of hepatitis C virus NS5A is required for NS5A dimerization and drug resistance.
    Lee WP; Tsai KC; Liao SX; Huang YH; Hou MC; Lan KH
    Life Sci; 2024 Jan; 337():122338. PubMed ID: 38072190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ser38-His93-Asn91 triad confers resistance of JFH1 HCV NS5A-Y93H variant to NS5A inhibitors.
    Lee WP; Tsai KC; Liao SX; Huang YH; Hou MC; Lan KH
    FEBS J; 2024 Mar; 291(6):1264-1274. PubMed ID: 38116713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylation of Serine 225 in Hepatitis C Virus NS5A Regulates Protein-Protein Interactions.
    Goonawardane N; Gebhardt A; Bartlett C; Pichlmair A; Harris M
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28615203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
    J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation.
    George A; Panda S; Kudmulwar D; Chhatbar SP; Nayak SC; Krishnan HH
    J Biol Chem; 2012 Feb; 287(7):5042-58. PubMed ID: 22184107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
    Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
    J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.
    Fridell RA; Qiu D; Valera L; Wang C; Rose RE; Gao M
    J Virol; 2011 Jul; 85(14):7312-20. PubMed ID: 21593143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Y-Box Binding Protein 1 Stabilizes Hepatitis C Virus NS5A via Phosphorylation-Mediated Interaction with NS5A To Regulate Viral Propagation.
    Wang WT; Tsai TY; Chao CH; Lai BY; Wu Lee YH
    J Virol; 2015 Nov; 89(22):11584-602. PubMed ID: 26355086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
    Nguyen D; Smith D; Vaughan-Jackson A; Magri A; ; Barnes E; Simmonds P
    J Hepatol; 2020 Oct; 73(4):794-799. PubMed ID: 32470499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein tyrosine kinase Abl promotes hepatitis C virus particle assembly via interaction with viral substrate activator NS5A.
    Miyamoto D; Takeuchi K; Chihara K; Fujieda S; Sada K
    J Biol Chem; 2022 Apr; 298(4):101804. PubMed ID: 35257746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serine 229 Balances the Hepatitis C Virus Nonstructural Protein NS5A between Hypo- and Hyperphosphorylated States.
    Tsai CN; Pan TC; Chiang CH; Yu CC; Su SH; Yu MJ
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents.
    Nitta S; Asahina Y; Matsuda M; Yamada N; Sugiyama R; Masaki T; Suzuki R; Kato N; Watanabe M; Wakita T; Kato T
    Sci Rep; 2016 Oct; 6():34652. PubMed ID: 27703205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C Virus Particle Assembly Involves Phosphorylation of NS5A by the c-Abl Tyrosine Kinase.
    Yamauchi S; Takeuchi K; Chihara K; Sun X; Honjoh C; Yoshiki H; Hotta H; Sada K
    J Biol Chem; 2015 Sep; 290(36):21857-64. PubMed ID: 26203192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures.
    Jeong Y; Jin B; Lee HW; Park HJ; Park JY; Kim DY; Han KH; Ahn SH; Kim S
    J Viral Hepat; 2018 Nov; 25(11):1251-1259. PubMed ID: 29768695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serine phosphorylation of the hepatitis C virus NS5A protein controls the establishment of replication complexes.
    Ross-Thriepland D; Mankouri J; Harris M
    J Virol; 2015 Mar; 89(6):3123-35. PubMed ID: 25552726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
    Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
    J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NS5A--from obscurity to new target for HCV therapy.
    Schmitz U; Tan SL
    Recent Pat Antiinfect Drug Discov; 2008 Jun; 3(2):77-92. PubMed ID: 18673121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.